NCT07556107 The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
| NCT ID | NCT07556107 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Bassett Healthcare |
| Condition | Infection |
| Study Type | INTERVENTIONAL |
| Enrollment | 852 participants |
| Start Date | 2026-08-17 |
| Primary Completion | 2028-06-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 852 participants in total. It began in 2026-08-17 with a primary completion date of 2028-06-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The VPT Safety Trial (VPS) compares two common antibiotic combinations to see how they affect the kidneys of patients in the hospital with serious infections. Both combinations are approved by the Food and Drug Administration (FDA). The goal is to help doctors know which combination is safer so they can make better choices for their patients.
Eligibility Criteria
Inclusion criteria 1. Hospitalized or being hospitalized. 2. Age \>/=18 yr old. 3. Serious or suspected serious infection for which VPT or VM considered a broad-spectrum combination antibiotic backbone standard of care by clinician. 4. Enrollment can be completed before the first dose of abx (ideally) and no later than before the second dose (alternatively). 5. Consenting/enrollment will not clinically significantly delay abx administration. 6. Baseline and \>/=1 prior Scr available (within 1 yr). 7. Pt or LAR able to provide IC. Exclusion criteria 1\. AKI (\>/=moderate) (KDIGO stage 2-3) (Scr increase \>/=2-fold from chronic BL) (Scr based). 2\. CKD (\>/=moderately to severely decreased eGFR) (KDIGO stage G3b-G5) (by history or eGFR \</=44 mL/min/1.73M2) (Scr based). 3\. Beta lactam allergy. 4. Contraindication to VPT or VM. 5. Infection requiring VPT or VM specifically or another abx regimen. 6. Participation in another research study with interventions that may impact study endpoints.
Contact & Investigator
Daniel Freilich, MD
PRINCIPAL INVESTIGATOR
Bassett Medical Center
Frequently Asked Questions
Who can join the NCT07556107 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Infection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07556107 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07556107 currently recruiting?
Yes, NCT07556107 is actively recruiting participants. Contact the research team at jennifer.victory@bassett.org for enrollment information.
Where is the NCT07556107 trial being conducted?
This trial is being conducted at Worcester, United States, Omaha, United States, Cooperstown, United States, Flushing, United States and 3 additional locations.
Who is sponsoring the NCT07556107 clinical trial?
NCT07556107 is sponsored by Bassett Healthcare. The principal investigator is Daniel Freilich, MD at Bassett Medical Center. The trial plans to enroll 852 participants.